Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.

The White House just announced that AstraZeneca and Pfizer will start charging foreign health systems the same prices for all newly launched treatments as they charge here in America. Bristol-Meyers ...

Pharmaceutical giant Pfizer has been circling its smaller rival for months. AstraZeneca has rejected every offer saying Pfizer undervalues the... Pfizer Drops $119 Billion Bid For AstraZeneca It would ...

Pfizer’s PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. Image Source: Zacks ...